Lupin has entered into an exclusive licensing, supply, and distribution agreement with Gan & Lee Pharmaceuticals, a China-based company, for Bofanglutide, an innovative GLP-1 receptor agonist administered biweekly for diabetes and weight management.

According to the agreement, Lupin will possess the exclusive rights to market and distribute the injectable medication in India. Bofanglutide, created by Gan & Lee, is given every two weeks and is designed for treating adults with type 2 diabetes, along with managing weight in those who are overweight and obese.

The medication is presented as a possible first-in-class global biweekly GLP-1 receptor agonist. Based on clinical data referenced by the companies, Bofanglutide has shown weight-loss results similar to or superior to current GLP-1 therapies, while providing the ease of less frequent dosing. The treatment additionally aids in reducing blood sugar levels and body weight, exhibiting a safety and tolerability profile aligned with the GLP-1 medication class.

Also Read: Semicon India 2025: Designing A Self-Reliant Semiconductor Hub

The collaboration enhances Lupin’s diabetes offerings as it seeks to bolster its position in the rapidly expanding obesity treatment market. Obesity is becoming a significant public health issue in India, with around 174 million adults deemed overweight and nearly 50 million categorized as obese. Diabetes currently impacts approximately 90 million adults nationwide.

Also Read: The Global Fintech Fest 2025: Enabling Finance for Better World

Nilesh Gupta, managing director, Lupin says, “We are offering the best solutions for managing chronic metabolic diseases like most urgent global health challenges. This partnership demonstrates our strategic focus on the GLP-1 class of drugs and highlights our dedication to delivering high-quality, innovative therapies for our patients.”

Also Read: 5 AI Initiatives by the Indian Government Driving National Growth

Rajeev Sibal, president, India region formulations, Lupin says, “Bofanglutide offers a significant advantage with its convenient fortnightly dosing, thus reducing the number of injections by 50 per cent while delivering outcomes and clinically proven efficacy that matches or surpasses existing weekly formulations.”